Efficacy of Etoricoxib on Peripheral Hyperalgesia
Causalgia, Polyneuropathy, Postherpetic Neuralgia
About this trial
This is an interventional treatment trial for Causalgia focused on measuring CRPS, Morbus Sudeck, Causalgia, Etoricoxib, Polyneuropathy, post herpetic neuralgia, peripheral nerve injury, radiculopathy, Nervenverletzung, postherpetische Neuralgie, COX-2-Inhibitor
Eligibility Criteria
Inclusion Criteria:
- Patients over 18 years with
- Persistent moderate or severe pain (> 4 on NRS (1..10)) at rest (average of three daily assessments using a diary for at least two days) .
- Neuropathic pain associated with a clinical and neurologically proven peripheral nerve injury, radiculopathy, postherpetic neuralgia or polyneuropathy or CRPS
One of the two following QST phenotypes at the baseline assessment:
- signs of peripheral hyperalgesia (that means, pathological decreased heat pain threshold and/or pathological decreased muscle pain threshold)
- without signs of peripheral hyperalgesia (no pathological decreased heat - and/or muscle pain threshold)
- Patients of both gender
- Signed consent form
- Patients with the ability to understand and follow the instructions of the doctor
Exclusion Criteria:
- Excluded will be patients Parkinson's disease or a history of cerebral vascular insult or nerve injury.
Excluded will be also all patients with contradictions for the use of Etoricoxib:
- Hypersensitivity to the active substance or to any of the excipients.
- Active peptic ulceration or active gastrointestinal (GI) bleeding.
- Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetyl-salicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.
- Pregnancy and lactation
- Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10).
- Estimated renal creatinine clearance <30 ml/min.
- Inflammatory bowel disease.
- Congestive heart failure (NYHA II-IV).
- Patients with hypertension whose blood pressure is persistently elevated above 140/90mmHg and has not been adequately controlled
- Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.
Intake of one of the following drugs (current or in the last 3 days)
- selective-serotonin-reuptake-inhibitor
- cetoconazole
- rifampicin
- phenytoin
- carbamazepine
- dexamethasone or other systemic corticoids
- traditional nonsteroidal antiphlogistics
- cyclooxygenase-inhibitors
- immunosuppressives
- TNF-α-inhibitors
Sites / Locations
- Bergmannsheil department of pain therapy
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Placebo Comparator
Placebo Comparator
etoricoxib, peripheral hyperalgesia
etoricoxib, no peripheral hyperalgesia
placebo, peripheral hyperalgesia
placebo, no peripheral hyperalgesia
14 patient with neuropathic pain and peripheral hyperalgesia get etoricoxib 90mg for 8 days
14 patients with neuropathic pain without peripheral hyperalgesia get etoricoxib 90mg for 8 days
14 patients with neuropathic pain with peripheral hyperalgesia get placebo for 8 days
14 patients with neuropathic pain without peripheral hyperalgesia get placebo for 8 days